A trademark for a preparation of botulinum toxin, used to treat blepharospasms, strabismus, and muscle dystonias and to smooth facial wrinkles.
Aesthetic Medicine has seen a dramatic increase in the diversity of the patients treated over the past decade and this trend is expected to continue to grow stronger than ever, with applications that cater to all people. – The American Society for Aesthetic Plastic Surgery (ASAPS), the leading national organization of board-certified plastic surgeons who specialize in cosmetic surgery, offers its predictions for cosmetic surgery in 2009.
Allergan Announces U.S. Food and Drug Administration (FDA) Approval of LATISSE(TM) — First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes. New Prescription Product Increases Length, Thickness and Darkness of Eyelashes. – Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
With the recent announcement by the United States Food and Drug Administration that there is an ongoing safety review of Botox Cosmetic (botulinum toxin type A), customers are looking for alternatives to treat frown lines between the brows. – Facial plastic surgeon Dr. D.J. Verret of Innovations Facial Plastic Surgery, Texas, USA, reported certain botox alternatives like temporary fillers such as hyaluronic acid can erase the lines by filling in the depression, or Surgiwire procedure can repair skin wrinkles and lines.
Ongoing safety review of Botox, Botox Cosmetic and Myobloc taking place in US. – The U.S. Food and Drug Administration today notified the public that Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using a wide range of doses.
Allergan, Inc. responds to Public Citizen’s allegation regarding a fatality following BOTOX(R) Cosmetic Treatment. – In response to public reports suggesting a causal link between a BOTOX(R) Cosmetic treatment in 2003 and a fatality, Allergan, Inc. (NYSE:AGN) provided further assurance to patients and the public about BOTOX(R) Cosmetic and BOTOX(R) (Botulinum Toxin Type A).
Botox and a similar injection Myobloc should come with stronger warnings following reports of 16 deaths after the botulinum toxin spread inside the body, a U.S. consumer group Public Citizen said.
– The Food and Drug Administration (FDA) should immediately increase its warnings and directly warn patients and doctors about the use of botulinum toxin ? available as Botox and Myobloc ? because of serious adverse reactions, including deaths, linked to the drug, Public Citizen said in a petition filed with the FDA.
